Compumedics Limited · ASX:CMP

Compumedics — Shareholder Meeting (October 2011)

19 slides from Compumedics's shareholder meeting presentation, October 2011

  1. Slide 1: Annual General Meeting October 2011

    C> COMPUMEDICS Annual General Meeting October, 2011 ‘Defining Life’s Signals’ — CG COMPUMEDICS Agenda ee Meeting opens Chairman's address Ordinary business Meeting closes

  2. Slide 2: Chairman's address / Overview

    CG COMPUMEDICS Chairman’s address Based on recent corporate “presentations GCOMPUMEDICS Overview Who is Compumedics A brief chronology A tradition of innovation Established client profile Established financials Product growth drivers Strategic growth drivers Market & Growth Outlook Strategic Growth

  3. Slide 3: Who is Compumedics?

    Who is Compumedics? + Compumedics is a global, leading innovator, designer and supplier of high-tech sleep, brain and ultrasonic blood-flow diagnostic monitoring systems + Compumedics is a technological leader - #1 Australia Sleep & Neurodiagnostics - #1\Japan Sleep - #1 China premier Sleep & TCD —

  4. Slide 4: Introduction: Board and Key Management

    Introduction Board and Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 23yrs mM, NED NED Mr Alen Anderson Prof. Graham Mitchell AO a Leading USAAttomney Preeminent Scienist CMP Tenure 10 yrs CMP Tenure 10 yrs i Mr. David Lawson Kerry Hubick, Ph.D Mr. Christoph Witte Mr War

  5. Slide 5: A brief chronology

    A brief chronology * 2004, acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. * 2006, awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. * 2

  6. Slide 6: Established Client Profile / Financial results FY2011

    oR National Aeronautics and Space Administration om Ue & MAYO CLINIC Collage of Medicine STANFORD UNIVERSITY Wo nwversiry oF MiciiGan Established Client PrOomer sas St VINCENT 'S HEALTH SB ric Unweastrvor Toxo _ @® Peking Unversity C@¥comPumeDIcs National Institutes of Health The Royal Children's @

  7. Slide 7: Established financials

    C5 COMPUMEDICS Established financials Results adjusted for medical innovations - AUDm Earnings adjusted for unrealised FX losses Medical diagnostic AUDm devices Medical Innovation As Reported FY2011 FY2010 FY2011 FY2010 FY2011 FY2010 Revenues 29.8 30.9 1.1 1.5 30.9 32.4 R&D expense 3.4 3.9 1.3 1.0 4

  8. Slide 8: Current trading - positive outlook

    Established financials _ EBITDA as reported, in constant currency & excluding medical innovations - AUDm EBITDA as reported and in constant currency (AUD) 2008 ire a ceo no oA aS a se ___ CE CONPUMEDICS Current trading — positive outlook >» Stated strategy of expanding sales resources 2 to 3 times i

  9. Slide 9: Product Growth Drivers: Treatment starts with diagnosis

    CG COMPUMEDICS ‘Product Growth Drivers Existing market: Treatment starts with diagnosis Sleep apnoea & Co-morbidities + Sleep apnoea represents a young market with the prevalence of related serious conditions (co-morbidities) rapidly increasing awareness since the turn of the millennium! + Most of t

  10. Slide 10: Product Growth Drivers: Home Sleep Testing in the USA

    Product Growth Drivers New market opportunity - Home Sleep sae Testing (HST) in the USA Compumedics Sleep Diagnostic Equipment Full PSG 2 16 channels (type 3) 2 18 channels (U) MY Sleep and respiratory Screening (type 2) 2 18 channels (A) M1 Respiratory home sleep testing (type 1) = 4 channels ir) (

  11. Slide 11: DWL Global Ultrasonic Blood Flow Monitoring

    Product Growtl DWL Global Ultrasonic Blood Flow Monitoring Products Provided + Doppler-Box: Digital Doppler device including Doppler M-Mode + EZ-Dop®: Very compact and portable Doppler device for routine diagnostics + Multi-Dop® T Series: Portable Doppler device with upgradeable bilateral monitoring

  12. Slide 12: Market & Growth Outlook

    Market & Growth Outlook Toran 2620 | cerry 3560 Diagnostics medical device businesses $100m+ $60m $35m Sleep diagnostics Brain research Now 3 to 5 years from now Go-Forward Strategic Mission: Strategic Growth Objectives _ CG cOMPUMEDICS Expand Compumedics sales force 2 to 3-fold as Compumedics augme

  13. Slide 13: Strategic Growth Execution: Clients in China

    ‘Strategic Growth Execution: Compumedics Clients in China “Compumedics is the number 1 supplier of premier sleep diagnostics in China” eee & £6 Compumedics is the preterred supplier for an @Xencha increasing number of leading researchers, : ©._5 @ruja universities and hospitals around the warid. Com

  14. Slide 14: Getting to $100m globally

    Getting to $100m globally US main engine of growth $11m to $35m through direct sales expansion Europe to triple €6m to €18m with increasing direct sales representatives in key German and French markets Asia to more than double $6m to $15m through expanding distribution network GUSA O Europe 2015 BAu

  15. Slide 15: Strategic Growth Execution: Capitalization Pathways

    Strategic Growth Execution Capitalization Pathways E<. The three principal paths available to Compumedics in order to implement the strategic growth drivers are: « “Do it ourselves” — recapitalise the group and implement the action plans for the strategic growth drivers ourselves (we are already doi

  16. Slide 16: Synergy & Strengths

    Strategic Growth Executio Synergy & Strengths > World Class Product Portfolio + Significant and innovative product range covering hardware and software solutions for the fast growing areas of sleep diagnosis & treatment, neuro-diagnostics, brain research and ultrasound brain blood flow + Broad and w

  17. Slide 17: What to look for from Compumedics

    What to look for from Compumedics GoCONPUMEDICS Establishment of new EEG long term monitoring (LTEM) reference sites Expansion of LTEM sales force Establishment of home sleep testing distribution channels Increased core business sales corresponding to expanded sales force, including increased focus

  18. Slide 18: Ordinary Business

    GOCOMPUMEDICS Ordinary Business = Item 1 Financial Statements and Reports = Item 2 Election of Director — Dr. Graham Mitchell = Item 3 Adoption of Remuneration Report (non binding resolution) _ CG COMPUMEDICS Meeting closes ee Refreshments and additional questions and discussion to continue in the m

  19. Slide 19: Thankyou

    Thankyou ‘Defining Life’s Signals’

Compumedics — Shareholder Meeting (October 2011) on 6ix